Press release
Hereditary Angioedema Treatment Market 2032: FDA Approvals, Clinical Trials, Drugs, Prevalence, Companies and Market Forecast by DelveInsight | KalVista Pharma, Intellia Therapeutics, BioMarin Pharma, CSL Behring, Ionis Pharma
DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.To Know in detail about the Hereditary Angioedema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hereditary Angioedema Market Forecast
https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key facts of the Hereditary Angioedema Market Report:
• The Hereditary Angioedema market size was valued approximately USD 2,300 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• 13,900 diagnosed prevalent cases of Hereditary Angioedema were reported in the 7MM in 2022; this number is predicted to rise at a significant CAGR by 2032.
• With around 1,400 cases, the UK had the highest diagnosed prevalence of Hereditary Angioedema among European nations in 2022. Germany came in second with 1,300 instances. However, with less than a thousand cases each in 2022, Spain and Italy had the lowest rates of diagnosed prevalent population.
• Type I, Type II, and Hereditary Angioedema with normal C1-INH (Type III) are the three categories for type-specific diagnosed prevalent instances of Hereditary Angioedema. Of them, Type I Hereditary Angioedema was responsible for the greatest number of cases in the 7MM in 2022.
• Due to the country's declining population, Japan's estimated 460 diagnosed prevalent cases of Hereditary Angioedema in 2022 are predicted to diminish marginally by 2032 at a respectable CAGR.
• Potential therapeutic targets include blocking the bradykinin-B2-receptor, plasma kallikrein inhibitor, inhibiting factor XII (for example, by using a blocking antibody), and preventing the cleavage of prekallikrein. In addition, a small number of gene treatments are being developed to treat Hereditary Angioedema; they will aid in the treatment of recently discovered mutations such FXII and PLG HAE.
• Key Hereditary Angioedema Companies: KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Intellia Therapeutics, Takeda, KalVista Pharmaceuticals, CSL Behring, Shire, and others
• Key Hereditary Angioedema Therapies: KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorse, STAR-0215, PHA121, NTLA-2002, TAK-743, KVD900, CSL312, Lanadelumab, and others
• The Hereditary Angioedema epidemiology based on gender analyzed that the diagnosed prevalent cases of Hereditary Angioedema in the 7MM varied according to gender, with prevalent cases higher in females than males
• The Hereditary Angioedema market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hereditary Angioedema pipeline products will significantly revolutionize the Hereditary Angioedema market dynamics.
Hereditary Angioedema Overview
Rarely occurring hereditary angioedema (HAE) is characterized by recurrent episodes of localized subcutaneous (SC) or mucosal edema, most commonly affecting the oropharynx, upper respiratory tract, skin, and intestines.
Get a Free sample for the Hereditary Angioedema Market Report:
https://www.delveinsight.com/report-store/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Hereditary Angioedema Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hereditary Angioedema Epidemiology Segmentation:
The Hereditary Angioedema market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Hereditary Angioedema
• Prevalent Cases of Hereditary Angioedema by severity
• Gender-specific Prevalence of Hereditary Angioedema
• Diagnosed Cases of Episodic and Chronic Hereditary Angioedema
Download the report to understand which factors are driving Hereditary Angioedema epidemiology trends @ Hereditary Angioedema Epidemiology Forecast
https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Hereditary Angioedema Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Angioedema market or expected to get launched during the study period. The analysis covers Hereditary Angioedema market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hereditary Angioedema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hereditary Angioedema Therapies and Key Companies
• KVD900: KalVista Pharmaceuticals
• NTLA-2002: Intellia Therapeutics
• BMN 331: BioMarin Pharmaceutical
• Garadacimab: CSL Behring
• Donidalorse: Ionis Pharmaceuticals
• STAR-0215: Astria Therapeutics
• PHA121: Pharvaris Netherlands B.V
• NTLA-2002: Intellia Therapeutics
• TAK-743: Takeda
• KVD900: KalVista Pharmaceuticals
• CSL312: CSL Behring
• Lanadelumab: Shire
Discover more about therapies set to grab major Hereditary Angioedema market share @ Hereditary Angioedema Treatment Market
https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Hereditary Angioedema Market Strengths
• Increasing identification of a novel genetic mutation in various regions warranting further focus on the types and associated pathophysiology, including recognition of hormonal changes
Hereditary Angioedema Market Opportunities
• Proliferating demand for therapies with improved patient compliance, fewer side effects, improved resistance profile, and long-acting therapies
Scope of the Hereditary Angioedema Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Hereditary Angioedema Companies: KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Intellia Therapeutics, Takeda, KalVista Pharmaceuticals, CSL Behring, Shire, and others
• Key Hereditary Angioedema Therapies: KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorse, STAR-0215, PHA121, NTLA-2002, TAK-743, KVD900, CSL312, Lanadelumab, and others
• Hereditary Angioedema Therapeutic Assessment: Hereditary Angioedema current marketed and Hereditary Angioedema emerging therapies
• Hereditary Angioedema Market Dynamics: Hereditary Angioedema market drivers and Hereditary Angioedema market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Hereditary Angioedema Unmet Needs, KOL's views, Analyst's views, Hereditary Angioedema Market Access and Reimbursement
To know more about Hereditary Angioedema companies working in the treatment market, visit @ Hereditary Angioedema Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Hereditary Angioedema Market Report Introduction
2. Executive Summary for Hereditary Angioedema
3. SWOT analysis of Hereditary Angioedema
4. Hereditary Angioedema Patient Share (%) Overview at a Glance
5. Hereditary Angioedema Market Overview at a Glance
6. Hereditary Angioedema Disease Background and Overview
7. Hereditary Angioedema Epidemiology and Patient Population
8. Country-Specific Patient Population of Hereditary Angioedema
9. Hereditary Angioedema Current Treatment and Medical Practices
10. Hereditary Angioedema Unmet Needs
11. Hereditary Angioedema Emerging Therapies
12. Hereditary Angioedema Market Outlook
13. Country-Wise Hereditary Angioedema Market Analysis (2019-2032)
14. Hereditary Angioedema Market Access and Reimbursement of Therapies
15. Hereditary Angioedema Market Drivers
16. Hereditary Angioedema Market Barriers
17. Hereditary Angioedema Appendix
18. Hereditary Angioedema Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports:
• Acute Heart Failure Ahf Market: https://www.delveinsight.com/report-store/acute-heart-failure-ahf-market
• Alstrom Syndrome Market: https://www.delveinsight.com/report-store/alstrom-syndrome-market
• Biliary Tract Carcinoma Market: https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market
• Chronic Plaque Psoriasis Market: https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
• Neurofibromatosis 2 Market: https://www.delveinsight.com/report-store/neurofibromatosis-2-market
• Penicillinbinding Proteins Market: https://www.delveinsight.com/report-store/penicillin-binding-proteins-market
• Acute On Chronic Liver Failure Aclf Market: https://www.delveinsight.com/infographics/acute-on-chronic-liver-failure-aclf-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Central Retinal Venous Occulsion Market: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
• Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market
• Community-acquired Bacterial Pneumonia Market: https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-market
• Cutaneous T-cell Lymphoma Market: https://www.delveinsight.com/infographics/cutaneous-t-cell-lymphoma-ctcl-market
• Idiopathic Membranous Nephropathy Market: https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-imn-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Clbp Market: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market
• Corneal Endothelial Dystrophy Market: https://www.delveinsight.com/report-store/corneal-endothelial-dystrophy-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Lymphocytopenia Market: https://www.delveinsight.com/report-store/lymphocytopenia-market
• Refractory Angina Market: https://www.delveinsight.com/report-store/refractory-angina-market
• Stable Angina Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Thrombocytopenia Market: https://www.delveinsight.com/report-store/thrombocytopenia-market
• Bacteremia Market: https://www.delveinsight.com/report-store/staphylococcus-aureus-bacteremia-market
• Achondroplasia Market: https://www.delveinsight.com/report-store/achondroplasia-market
• Beta Thalassemia Market: https://www.delveinsight.com/report-store/beta-thalassemia-market
• Acute Pharyngitis Market: https://www.delveinsight.com/report-store/acute-pharyngitis-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market
• Chronic Hepatitis Delta Virus Market: https://www.delveinsight.com/infographics/hepatitis-d-market
• Heavy Metal Poisoning Market: https://www.delveinsight.com/report-store/heavy-metal-poisoning-market
• Hepatorenal Syndrome Market: https://www.delveinsight.com/report-store/hepatorenal-syndrome-market
• Hypoparathyroidism Market: https://www.delveinsight.com/report-store/hypoparathyroidism-market
• Ventricular Dysfunction Market: https://www.delveinsight.com/report-store/ventricular-dysfunction-market
• Chronic Obstructive Pulmonary Disease Copd Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Chronic Pruritus Market: https://www.delveinsight.com/report-store/chronic-pruritus-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hereditary Spastic Paraplegias Market: https://www.delveinsight.com/report-store/hereditary-spastic-paraplegias-market
• Advanced Renal Cell Carcinoma Market: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/sample-request/familial-primary-pulmonary-hypertension-market
• Healthcare Pipeline Analysis: https://www.delveinsight.com/consulting/pipeline-assessment-services
• Optic Neuritis Market: https://www.delveinsight.com/report-store/optic-neuritis-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment
• Post Traumatic Stress Disorder Market: https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-market
• Spasticity Market: https://www.delveinsight.com/report-store/spasticity-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market
• X Linked Hypophosphatemia Market: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Wegener S Granulomatosis/granulomatosis With Polyangiitis Market: https://www.delveinsight.com/report-store/wegeners-granulomatosis-market
• Artificial Lung Devices Market: https://www.delveinsight.com/report-store/artificial-lung-devices-pipeline-insight-and-competitive-landscape
• Diabetic Foot Ulcers Dfus Market: https://www.delveinsight.com/infographics/diabetic-foot-ulcers-dfus-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hereditary Angioedema Treatment Market 2032: FDA Approvals, Clinical Trials, Drugs, Prevalence, Companies and Market Forecast by DelveInsight | KalVista Pharma, Intellia Therapeutics, BioMarin Pharma, CSL Behring, Ionis Pharma here
News-ID: 3627362 • Views: …
More Releases from DelveInsight Business Research

Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…

Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…

Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…

Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Hereditary
Hereditary Angioedema Market: An In-Depth Analysis
In 2024, the market for Hereditary Angioedema Market was valued at USD 3.1 billion. It is anticipated to grow to USD 5.9 billion by 2033, with a CAGR of 6.82% over the period 2026-2033.
Hereditary Angioedema Market Overview
The global hereditary angioedema therapeutics market is experiencing significant expansion, driven by increasing awareness, improved diagnostic capabilities, and the introduction of novel treatment options. Advances in genetic research have enabled early and accurate…
Leber Hereditary Optic Neuropathy Treatment Market
Introduction
Leber Hereditary Optic Neuropathy (LHON) is a genetic condition that leads to severe vision loss, primarily affecting young adults. This disorder is caused by mutations in mitochondrial DNA, which impairs the function of retinal ganglion cells. As awareness of LHON has grown, so too has the focus on its treatment options. The LHON treatment market is evolving rapidly, driven by advancements in genetic therapies, pharmaceuticals, and supportive care strategies. This…
Hereditary Hemochromatosis Market - Redefining Care, Inspiring Hope: Hereditary …
Newark, New Castle, USA: The "Hereditary Hemochromatosis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Hereditary Hemochromatosis Market: https://www.growthplusreports.com/report/hereditary-hemochromatosis-market/8793
This latest report researches the industry structure, sales, revenue,…
Hereditary Angioedema Market Research Report 2032
DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Global Hereditary Angioedema Market report from Global Insight Services is the single authoritative source of intelligence on hereditary angioedema market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Hereditary Angioedema is an infrequent inherited disease that causes substantial swelling in various body tissues, such as the abdomen or face caused by a low level or improper function of a protein called the C1 inhibitor. There are three types of hereditary angioedema namely type I, II, and III.
Hereditary Angioedema is mainly caused by a low level or improper function of a protein called the C1 inhibitor.
Read more about Hereditary…